Invesco International Dividend Achievers ETF (PID)
NASDAQ: PID · Real-Time Price · USD
22.19
+0.34 (1.56%)
Oct 15, 2026, 4:00 PM EDT - Market closed
| Assets | $859.62M |
| Expense Ratio | 0.53% |
| PE Ratio | 14.25 |
| Forward PE | 12.59 |
| Shares Out | 39.51M |
| Dividend | $0.78 (3.53%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 50.29% |
| Volume | 52,037 |
| Open | 21.99 |
| Previous Close | 21.85 |
| Day's Range | 21.97 - 22.23 |
| 52-Week Low | 21.17 |
| 52-Week High | 23.76 |
| Beta | 0.72 |
| Holdings | 66 |
| Inception Date | Sep 15, 2005 |
About PID
Fund Home PageThe Invesco International Dividend Achievers ETF (PID) is an exchange-traded fund that mostly invests in total market equity. The fund tracks a dividend-yield-weighted index of foreign securities with high dividend growth. PID was launched on Sep 15, 2005 and is issued by Invesco.
Asset Class Equity
Category Foreign Large Value
Region Global
Stock Exchange Nasdaq
Ticker Symbol PID
ETF Provider Invesco
Index Tracked NASDAQ International Dividend Achiever Index
Top 10 Holdings
33.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Itaú Unibanco Holding S.A. | ITUB | 5.29% |
| Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk | TLK | 3.64% |
| British American Tobacco p.l.c. | BTI | 3.53% |
| TELUS Corporation | T | 3.49% |
| FinVolution Group | FINV | 3.41% |
| Enbridge Inc. | ENB | 3.03% |
| Sanofi | SNY | 2.87% |
| Eni S.p.A. | E | 2.76% |
| Brookfield Infrastructure Partners L.P. | BIP | 2.68% |
| Brookfield Infrastructure Corporation | BIPC | 2.65% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 21, 2026 | $0.15416 | Sep 25, 2026 |
| Jun 22, 2026 | $0.31287 | Jun 26, 2026 |
| Mar 23, 2026 | $0.19759 | Mar 27, 2026 |
| Dec 22, 2025 | $0.11851 | Dec 26, 2025 |
| Sep 22, 2025 | $0.17214 | Sep 26, 2025 |
| Jun 23, 2025 | $0.26366 | Jun 27, 2025 |
Performance
PID had a total return of 8.50% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.47%.
News
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Other symbols: TAK
5 months ago - Business Wire